The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

A new study from the USC Norris Comprehensive Cancer Center has found evidence that targeting CD47, a protein that is part of ...

From James Van Der Beek spreading awareness about colorectal cancer at a younger age to Gerry Connolly’s recent esophageal ...

A new study from the USC Norris Comprehensive Cancer Center has found evidence that targeting CD47, a protein that is part of ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

Agenus Inc. ( (AGEN) ) has released its Q3 earnings. Here is a breakdown of the information Agenus Inc. presented to its investors. Agenus Inc.

It is one of the first indications that targeting part of the innate immune system, combined with traditional immunotherapy drugs which work on the adaptive immune system, could be more effective in ...

A new USC study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer. It is one of the first indications that ...

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair ...